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1. Introduction
The aging of the population is a worldwide phenomenon, and studying age-related diseases
has become a relevant issue from both a scientific and a public health perspective. Dementia
is a syndrome characterised by loss of cognitive abilities in multiple domains that results in
impairment in normal activities of daily living and loss of independence [1]. Both prevalence
and incidence of dementia rise exponentially with advancing age, and 70% of all dementia
cases occur in people aged 75+ years [2]. The worldwide increase in the number of older adults,
more pronounced in the 80+ age group, explains the epidemic proportions assumed by
dementia. According to the World Alzheimer Report, there were 35.6 million people living
with dementia worldwide in 2010, a number that will increase to 65.7 million by 2030 and 115.4
million by 2050 unless effective means reducing the disease incidence are introduced [3].
Dementia is a major cause of disability and institutionalization of elderly people and because
of its increased prevalence this disorder is becoming an emerging public health issue not only
in developed countries but also in less developed regions of the world. The total estimated
worldwide costs of dementia were US$604 billion in 2010, including the costs of informal care
(unpaid care provided by family and others), direct costs of social care (provided by com‐
munity care professionals, and in residential home settings) and the direct costs of medical
care (the costs of treating dementia and other conditions in primary and secondary care) [3].
Alzheimer’s disease (AD) is considered the most common cause of dementia, accounting for
60–70% of all dementia cases. The hallmarks of AD neuropathology in the brain are the
presence of extracellular plaques composed of amyloid-β (Aβ) and intracellular neurofibrillary
tangles (NFTs) composed of hyperphosphorylated aggregates of the microtubule-associated
tau protein [4].
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Vascular dementia (VaD), mainly due to cerebrovascular diseases (CVD), is the second most
frequent type of dementia [5, 6]. This current classification of dementia types is being recon‐
sidered in light of recent neuropathological and neuroimaging studies, which have shown a
range of dementia-associated brain abnormalities from pure vascular lesions at one end to pure
AD pathologies at the other, with most dementia cases being attributable to both CVD and
AD. In fact, AD and CVD-related changes often coexist in the brain of older adults with
dementia and mild cognitive impairment (MCI) [7, 8]. Also, both types of lesions are detected
in the brain of cognitively normal elderly people, highlighting the importance of mixed
pathologies in increasing the risk of late-life dementia [9]. The co-occurrence of AD and CVD
is consistent with the evidence that AD and VaD share several risk and protective factors,
including cardiovascular and lifestyle related factors. Overall, this implies that dementia
syndrome is a valid target for prevention, especially from the public health perspective.
Prevention is traditionally divided into three levels: primary, secondary, and tertiary preven‐
tion. Primary prevention aims to reduce the incidence of the disease by eliminating or treating
specific risk factors, which may decrease or delay the development of dementia. Secondary
prevention aims to early detection of the disease, before any symptom has emerged, when
treatment could stop its progression. Tertiary prevention aims to reduce the impact of
complications and disability of long-term diseases.
Regarding primary prevention, both observational and interventional epidemiological studies
have been conducted for dementia and AD. On the other hand, in the field of AD the devel‐
opment of pharmacological interventions has been mainly limited to a tertiary prevention
level, since the diagnostic criteria currently in use for AD (National Institute of Neurological
and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders
Association, NINCDS-ADRDA - criteria) identify the presence of the disease only when AD
is severe enough to cause a dementia syndrome [10]. Thus, the majority of anti-AD drugs have
been tested in subjects already in the symptomatic stage of the disease, and so far no drug has
shown the ability to stop the disease progression (i.e. disease-modifying effect) [11]. However,
several studies have shown that the pathophysiological process of AD begins years, if not
decades, before the diagnosis of Alzheimer’s dementia and individuals generally experience
a gradual impairment of cognitive functions, which can progress to a dementia syndrome
[12-14].
Recent advances in neuroimaging, cerebrospinal fluid (CSF) assays, and other techniques now
provide the ability to detect evidence of the AD pathophysiological process in vivo, but the
diagnostic criteria currently in use do not take into account these biomarkers. Three interna‐
tional workgroups promoted by the American National Institute of Aging (NIA) and the
American Alzheimer’s Association recently proposed new diagnostic guidelines to identify
dementia due to AD, MCI due to AD, and preclinical AD [15-17]. These new criteria formalize
the different clinical stages of AD and incorporate biomarkers (genetic, biochemical, neuroi‐
maging) that can be detected in vivo and are believed to reflect AD pathology. These diagnostic
criteria are now being validated and can be revised as long as new findings from research on
biomarkers in AD will clarify the link between AD pathophysiology and the AD clinical
syndrome. These criteria offer the opportunity to identify subjects who can be target of
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secondary prevention in order to halt the progression of the brain damage and prevent or delay
the onset of cognitive symptoms. A step in this direction has been done by planning random‐
ized controlled trials (RCTs) testing anti-amyloid drugs in older adults with evidence of brain
amyloid accumulation. The same type of intervention will also be tested in subjects at risk of
early onset AD due to genetic mutations associated with familial AD.
This chapter summarizes the major findings concerning primary prevention of late onset
dementia and AD, based on current epidemiological evidence from observational and
interventional studies. Preventive strategies for early onset AD are also mentioned. Although
many aspects of the dementias are still unclear, some risk and protective factors have been
identified. It is also possible to delineate some preventative strategies. Ongoing interventional
studies testing the effect of preventive measures for dementia and AD are discussed, and
methodological challenges in designing dementia prevention trials are summarized.
2. Observational studies
Several community-based prospective studies of aging and health have been carried out in
different countries since the 80s’. These studies have provided relevant information on the
aetiology of dementia and AD, and have led to the identification of possible preventive
strategies. Evidence from these observational studies has shown that dementia is a multifac‐
torial disorder caused by several interrelated mechanisms in which the interaction of genetic
and environmental factors plays the major role (Table 1). The pathways that lead from different
risk factors to dementia are not fully understood, but several etiological hypotheses have been
proposed: the vascular hypothesis, inflammatory hypothesis, oxidative-stress hypothesis,
toxic hypothesis and psychosocial hypothesis [18, 19]. These theories highlight potential links
of various risk factors to both the vascular and the neurodegenerative brain pathologies that
can cause dementia, supporting the validity of dementia syndrome as target for prevention [6,
20].
2.1. Non-modifiable risk factors for Alzheimer’s disease
Both modifiable and non-modifiable risk factors have been identified for dementia and AD,
and while for some factors the scientific evidence is quite robust, for others the results are still
inconclusive.
2.1.1. Age
Increasing age is a well-established risk factor for dementia, which is a common disorders after
75 years of age, but rare before age 60. The incidence rates of dementia increase exponentially
with advancing age. In Europe, approximately two per 1,000 person-years become demented
among people aged 65-69 years, and the incidence increases to 70 to 80 per 1,000 person-years
for people 90 years or over [21, 22]. It is still unclear if the incidence of dementia continues to
increase even in the oldest old or reaches a plateau at a certain age. The Cache County Study
found that the incidence of dementia increased with age, peaked, and then started to decline
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at extreme old ages for both men and women. However, some meta-analyses and large-scale
studies in Europe provided no evidence for the potential decline in the incidence of dementia
among the oldest old [21, 22].
Risk factors Protective factors Combined effects 
Age 
Genetic 
Familial aggregation 
APOE ε4 
APP 
GSK3β 
DYRK1A 
Tau 
CLU 
TOMM40 
PICALM 
CR1 
 
Vascular 
Cerebrovascular lesions 
Cardiovascular diseases 
Diabetes mellitus and pre-diabetes 
Midlife positive association but late-life 
negative association 
Hypertension  
High BMI (overweight and obesity) 
High serum cholesterol  
 
Lifestyle 
Smoking  
High alcohol intake 
 
Diet 
Saturated fats 
Homocysteine 
 
Others 
Depression 
Occupational exposure 
Traumatic brain injury 
Infective agents (Herpes Simplex 
Virus Type I, Clamydophila 
pneumoniae, Spirochetes) 
Genetic 
APP 
 
Psychosocial factors  
High education and SES 
High work complexity 
Rich social network and social 
engagement 
Mentally stimulating activity 
 
Lifestyle  
Physical activity 
 
Diet 
Mediterranean diet 
Polyunsaturated (PUFA) and fish-
related fats 
Vitamin B6, B12, folate  
Antioxidant vitamins (A, C, E) 
Vitamin D 
 
Drugs 
Statins 
Antihypertensive drugs 
HRT 
NSAIDs 
 
 
Increased risk 
Genetic and environmental factors in 
midlife 
APOEε4 magnifies the effect of high 
alcohol intake, smoking, physical 
inactivity and high intake of saturate fat 
 
Vascular factors in midlife  
Hypertension, obesity, 
hypercholesterolemia and physical 
inactivity have an additive effect when 
they co-occur 
 
Vascular factors/diseases in late-life 
Higher risk in individuals with brain 
hypoperfusion profile: chronic heart 
failure, low pulse pressure, low diastolic 
pressure 
Higher risk in individuals with 
atherosclerosis profile: high systolic 
pressure, diabetes mellitus or 
prediabetes, stroke 
 
Decreased risk 
Genetic and environmental factors in 
midlife 
High education reduces the negative 
effect of APOEε4  
Physical activity counteracts the risk due 
to APOEε4 
 
Environmental factors in midlife 
High work complexity modulates the 
increased dementia risk due to low 
education 
 
Genetic and environmental factors in late-
life 
Active leisure activities or absence of 
vascular risk factors reduces the risk due 
to APOEε4 
 
 
APOE: apolipoprotein E. BMI: body mass index. CLU: clusterin. CR1: complement component receptor 1. DYRK1A:
dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A. GSK3β: glycogen synthase kinase-3beta. HRT:
hormone replacement therapy. NSAIDs: nonsteroidal anti-inflammatory drugs. PICALM: phosphatidylinositol
binding clathrin assembly protein. PUFA: polyunsaturated fatty acid. SES: socioeconomic status. TOMM40:
translocase of outer mitochondrial membrane 40 homolog.
Table 1. Proposed risk and protective factors for dementia and Alzheimer’s disease
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2.1.2. Familial aggregation
Familial aggregation is another important risk factor for late life dementia and AD. First-degree
relatives of AD patients have a higher lifetime risk for developing AD than relatives of non-
demented people or the general population (Table 1) [21, 22]. It is likely that shared genetic
and environmental factors contribute to the familial aggregation. The amount of risk of AD
that is attributable to genetics is estimated to be around 70% [25].
2.1.3. Genes
The Apolipoprotein E (APOE) ε4 allele is the only established genetic risk factor for both early-
and late-onset AD; it is a susceptibility gene, being neither necessary nor sufficient for the
development of AD. The risk of AD increases with increasing number of the ε4 alleles in a
dose-dependent manner, but the risk effect decreases with increasing age. Individuals with
two APOE ε4 alleles have a more than seven times increased risk of developing AD compared
with those with APOE ε3 alleles and approximately 15 to 20 percent of AD cases are attributable
to the APOE ε4 allele [25-28].
Other genes have been related to increased risk of late life AD, but the association is less
consistent.  These  are  mainly  genes  involved  in  the  metabolism  and  processing  of  the
amyloid  precursor  protein  (APP)  and Aβ,  as  well  as  tau  protein,  including  the  GSK3β,
DYRK1A, Tau, and CLU genes [25]. Until now, mutations in APP have not been implicat‐
ed in the late-onset form of AD, with the exception of the rare variant, N660Y, which was
recently  identified in  one case  from a  late-onset  AD family  [29].  A recent  study identi‐
fied a mutation in the APP gene that can be protective against AD and age-related cognitive
decline.  This  mutation is  associated with a  reduced production of  amyloidogenic  pepti‐
des [30]. Other genes that have been associated with increased risk of AD are TOMM40,
CR1 and PICALM. The TOMM40 gene is located in a region of chromosome 19, which is
in linkage disequilibrium with APOE,  and its  polymorphism affects the age on onset  of
AD in subjects with an APOE genotype [31]. CR1 is involved in the complement cascade,
while  PICALM  encodes  a  protein  that  is  involved  in  clathrin-mediated  endocytosis,  an
essential step in the intracellular trafficking of proteins and lipids such as nutrients, growth
factors and neurotransmitters [32].
Several aspects challenge the identification of genetic risk factors for late life AD, including
the fact that risk conferred by a single gene is generally small, and for some genes is the
combination of risk alleles that is relevant for a significant change of the overall risk. Also, the
heterogeneous and mixed nature of brain pathology causing dementia, particularly coexisting
CVD, makes it more difficult to identify genetic risk factors for AD. Nevertheless, the identi‐
fication of genetic risk factors for late onset AD can have implication for preventive and
therapeutic strategies. In fact, it has been shown that the APOE ε4 allele can modulate the effect
of lifestyle related risk factors [33] and influence the effect of pharmacological treatment for
AD [34]. It is thus possible that future preventive and therapeutic measures will be tailored
according to specific genetic risk profiles.
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2.2. Modifiable risk and protective factors for Alzheimer’s disease
Different modifiable factors have been proposed to play a role in late life dementia and AD,
including nutritional factors (i.e., diet and nutritional supplements), social or economic factors,
medical conditions and lifestyle related factors (e.g., smoking habit, physical activity, etc.)
(Table 1). A report commissioned by the National institute of Health (NIH) to the Agency for
Healthcare Research and Quality (AHRQ) was published in 2010, and concluded that current
research evidence on many risk and protective factors for cognitive decline and AD is not of
sufficient strength, thus recommendations for preventing these conditions cannot be made [35,
36]. Another previous review yielded similar conclusions [37]. These negative perspectives
have been criticized, since there is consistent and robust epidemiological evidence that use of
antihypertensive medications, cessation of smoking and increasing physical activity produces
cognitive benefits in older adults [38]. Furthermore, the analytical strategy used in the Evidence
Based Review carried out by the AHRQ did not take into account the life-course perspective
[39]. Observational longitudinal studies have shown that the risk of late-life dementia and AD
is determined by exposures to multiple factors experienced over the life-span and that the
effect of specific risk/protective factors largely depends on age [39]. Thus, a life-course
perspective is relevant for chronic disorders with a long latent period (such as dementia). It
allows the identification of time windows when exposures have their greatest effect on
outcome and assessment of whether cumulative exposures could have multiplicative or
additive effects over the life course [40]. Age-dependent associations with AD have been
suggested for several aging-related medical conditions. For example, elevated blood pressure,
body mass index (BMI) and total cholesterol levels at a young age and in middle age (<65 years)
have been associated with an increased risk of dementia and AD, whereas having lower values
in late life (age >75 years) has been also associated with subsequent development of dementia/
AD [41-46].
2.2.1. Risk factors
1. Vascular risk factors and disorders: An association of elevated blood pressure in midlife
with an increased risk of dementia and AD later in life has been reported in several
population-based studies [41, 47], while follow-up studies of late-life blood pressure and
risk of dementia yield mixed results, largely depending on the length of follow-up. The
short-term follow-up studies (e.g., less than 3 years) often found no association or even
an inverse association between blood pressure and risk of dementia and AD [41].
However, studies of very old people (i.e., 75 + years) with a longer follow-up period (i.e.,
more than 6 years) also revealed an increased risk of dementia associated with low blood
pressure [48], suggesting that among very old people low blood pressure may also
contribute to the development of dementia, possibly by influencing cerebral blood
perfusion.
For BMI, the bidirectional association with dementia and AD has been shown in several
studies, and longitudinal studies of elderly people have associated accelerated decline in
BMI with subsequent development of dementia. This implies that low BMI and weight
loss in advanced age can be interpreted as markers for preclinical dementia [45, 46, 49-55].
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Regarding serum total cholesterol, the importance of the pattern of change in cholesterol
levels after midlife has been shown by two studies with a long follow-up, reporting that
a decline in plasma total cholesterol after midlife may be associated with the risk of
cognitive decline, dementia and AD in late life [56, 57]. These findings suggest that high
total serum cholesterol in midlife seems to be a risk factor for dementia and AD in
advanced age, while decreasing serum cholesterol after midlife may reflect ongoing
disease processes and represent a marker of early stages in the development of dementia
and AD. The use of statins (cholesterol-lowering drugs) in relation to dementia has been
investigated in several community studies, with mixed findings. Some observational
studies suggest a protective effect, while others did not, and clinical trials using statins
for prevention of cognitive decline or dementia mainly reported no effects [6, 58]. Diabetes
mellitus has been associated with increased risk of dementia and AD over adult life, but
the risk is stronger when diabetes occurs in mid-life than in late-life [59]. Also pre-diabetes,
impaired glucose regulation, and impaired insulin secretion have been associated with
and increased risk of dementia and AD [60].
Cerebrovascular lesions and cardiovascular diseases have been shown to be risk factors
for dementia and AD. Several population-based studies reveal an approximately two- to
four-fold increased risk of incident dementia associated with clinical stroke (post-stroke
dementia) [61, 62]. It is probable that an association of clinical stroke with AD is rarely
reported due to the fact that a history of stroke is part of the current criteria for excluding
the diagnosis of AD. However, asymptomatic cerebrovascular lesions such as silent brain
infarcts and white matter lesions have been associated with an increased risk of dementia
and AD [63, 64], although the association with AD is likely to be due to the inclusion of
mixed dementia cases. The Cardiovascular Health Study found that cardiovascular
disease was associated with an increased incidence of dementia, with the highest risk seen
among people with peripheral arterial disease, suggesting that extensive peripheral
atherosclerosis is a risk factor for dementia [65]. Atrial fibrillation, heart failure, and severe
atherosclerosis measured with ankle-to-brachial index are also associated with the
increased risk of dementia and AD [66-69].
2. Environmental and other factors: Current smoking is another major risk factor for
dementia and AD, and based on the worldwide prevalence of smoking, about 14% of all
AD cases are potentially attributable to this risk factor [70]. Although it is not entirely clear
whether depression is a risk factor for or a preclinical symptom of dementia, studies with
long-term follow-up support the risk-factor hypothesis [71]. Other conditions have been
proposed as risk factors for dementia and AD, but the evidence is still sparse. These
include occupational exposure, traumatic brain injury and infections. Occupational
exposure to heavy metals such as aluminum and mercury has been suggested to be a risk
factor for AD; even high consumption of aluminum from drinking water has been
associated with an elevated risk of AD and dementia [6, 72]. In addition, occupational
exposure to extremely-low-frequency electromagnetic fields (ELF-EMFs) has been related
to an increased risk of dementia and AD [73, 74].
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Traumatic brain injury has been extensively investigated as a possible risk factor for AD.
The meta-analysis of case-control studies supported an association between a history of
head injury and the increased risk of AD [75]. In contrast, some longitudinal studies found
that AD was not associated with head trauma or only associated with severe traumatic
head injury [76]. The role of viral and bacterial organisms in the development of chronic
neurodegeneration is long established. Thus, Treponema pallidum and HIV, in particular,
have been associated with the development of dementia. Other infections in the central
nervous system (CNS), particularly Herpes Simplex Virus Type 1, Chlamydophila
pneumoniae and several types of Spirochetes, have been suggested as possible aetiological
agents in the development of sporadic AD, but with little consistent evidence. It has also
been suggested that peripheral infections may have a role in accelerating neurodegener‐
ation in AD by activating already primed microglial cells within the CNS [77].
2.2.2. Protective factors
1. Psychosocial factors: Protective factors for dementia and AD have also been identified,
including high education and socioeconomic status (SES) in early life as well as a number
of factors in adult life: high work complexity, rich social network, social engagement,
mentally-stimulating activity, non-smoking and regular physical exercise [6, 78, 79].
Living with a partner during mid-life has been associated with reduced risk of cognitive
impairment and dementia later in life, suggesting that being in a relationship entails
cognitive and social challenges that can increase the cognitive reserve [80]. Even at old
ages the active engagement in mental, physical and social activities may postpone the
onset of dementia, possibly by increasing the cognitive reserve [81].
2. Lifestyle and diet: In addition, several follow-up studies reported a decreased risk of
dementia and AD associated with healthy dietary patterns and nutritional factors, such
as high adherence to a Mediterranean diet or dietary intake of antioxidants (e.g., vitamins
E and C) and ω-3 polyunsaturated fatty acid (PUFA, often measured as fish consumption)
[82-86], although some negative results have been also reported [87-90]. Light-to-moder‐
ate alcohol intake (e.g., 1-3 drinks per day) has been associated to a reduced incidence of
dementia and AD [6, 91, 92], while heavy alcohol consumption at midlife has been
associated to an increased risk of dementia/AD, especially among APOE ε4 carriers [93].
Alcohol may have beneficial influences on several cardiovascular factors, including lipid
and lipoprotein levels, inflammatory and hemostatic factors. Indeed, moderate alcohol
drinking has been related to a reduced risk of cardiovascular diseases, and may be
associated with fewer brain infarcts [6]. However, it has been also suggested that the
apparent cognitive benefits of light-to-moderate alcohol intake could be due to potential
biases that result from methodological limitations of the observational studies such as
information bias, confounding of socioeconomic status and healthy lifestyles, and
inconsistent approaches of alcohol assessments [6].
3. Vitamins: The micronutrient vitamin E is the main lipid-soluble, chain-breaking, non-
enzymatic antioxidant in the human body [94], and is essential for normal neurological
functions [95]. Vitamin E includes eight natural congeners: four tocopherols and four
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tocotrienols, named as α, β, γ, and δ [96]. Each congener shows different biological
properties potentially relevant for neuroprotection. These include antioxidant and anti-
inflammatory activity and modulation of signaling pathways involved in neurodegener‐
ation [96, 97]. Most investigation of vitamin E in relation to dementia and AD has focused
primarily only on α-tocopherol, with conflicting findings. Overall, studies investigating
vitamin E intake only from supplements found no association with dementia/AD risk [89,
98-101], or a reduced incidence was found only for the combined use of vitamin E and C
supplements [102, 103]. On the other hand, studies examining vitamin E dietary intake
consistently report a reduced risk of dementia/AD in individuals with high vitamin E
intake [84, 85, 104-106]. This might be explained by the fact that while vitamin E supple‐
ments contain only α-tocopherol, dietary intake can provide a balanced combination of
different forms of vitamin E, which can be more relevant for neuroprotection. Recent
studies seem to support this hypothesis: a multicenter European study found that both
AD and MCI were associated with low plasma tocopherols and tocotrienols levels [107].
Further, in the Swedish Kungsholmen Project a decreased AD risk was found in subjects
with high plasma levels of total tocopherols and total tocotrienols [108].
Vitamin B12 and folate are essential micronutrients that are part of the homocysteine
metabolic cycle, and both vitamin B12 and folate deficiencies can result in increased total
homocysteine levels, which may lead to a variety of disorders including cardiovascular
and cerebrovascular conditions. Several studies reported and increased risk of dementia/
AD, worse cognitive functioning and structural brain changes in individuals with low
levels of vitamin B12, holotranscobalamin (the biologically active fraction of vitamin B12)
or folate, or high levels of total homocysteine [109-115]. Other studies did not confirm
these findings, but methodological differences (e.g., different follow-up duration,
implementing the study after mandatory folic acid fortification, etc.) could account for the
discrepancy [116-119]. Reviews of RCTs concluded that supplementations of folic acid
and vitamin B12 had no benefits on cognition in healthy or cognitively impaired older
people, although they were effective in reducing serum homocysteine levels [120, 121]. A
more recent RCT testing the efficacy of B vitamins (B6, B12, folate) in subjects with MCI
reported beneficial effects of the supplementation, in terms of reduced rate of brain
atrophy and cognitive decline, which were more evident in subjects with elevated
homocysteine levels [122, 123].
Vitamin D is a secosteroid hormone that is suggested to have neuroprotective effects that
include regulation of neuronal calcium homeostasis, as well as antioxidant, neurotrophic
and anti-inflammatory properties. Few recent longitudinal studies found a reduced risk
of cognitive decline or AD in subjects with higher blood levels or higher dietary intake of
vitamin D [124-126]. Despite the epidemiological evidence is still weak vitamin D is
already being tested as a therapeutic agent in AD [127].
2.2.3. Combined effect
Cumulative and combined exposure to different risk factors can lead to modified effects on
dementia/AD risk (Table 1). In the Finnish Cardiovascular Risk Factors, Aging, and Dementia
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study (CAIDE), the risk of dementia has been evaluated in relation to a score (CAIDE Dementia
Risk Score) combining mid-life risk factors, including low education and cardiovascular factors
(i.e., hypertension, obesity, hypercholesterolemia, physical inactivity). The risk of dementia
increased as the score increased in a dose-response trend, making it possible to identify
individuals who can greatly benefit from preventive intervention that targets vascular risk
factors [128]. Similar findings have been reported for late-life exposures: in the Swedish
Kungsholmen Project, the cumulative effect of vascular risk factors and vascular diseases on
dementia/AD risk has been investigated in people aged 75+ years. These factors were aggre‐
gated according to two pathophysiological hypotheses: the brain hypoperfusion profile,
defined by chronic heart failure, low pulse pressure, and low diastolic pressure, and the
atherosclerosis profile, which included high systolic pressure, diabetes mellitus or prediabetes,
and stroke. In both profiles, dementia/AD risk increased with increasing scores in a dose-
response manner, suggesting a synergy of vascular risk factors in promoting dementia/AD
also in advanced age [129]. The American Cardiovascular Health Cognition Study developed
a Late-life Dementia Risk Index, and also its brief version, which groups older adults in the
three categories of low, moderate, and high risk of developing dementia. Both versions of the
index support the cumulative effect of different factors in determining the risk of dementia
after the age of 65 years. These indices include information from different domains, including
demographic factors (age), genetic (presence of the APOE ε4 allele), lifestyle (BMI<18.5, lack
of alcohol consumption), comorbid vascular conditions (internal carotid artery thickening,
angina, coronary artery by-pass surgery, stroke, peripheral artery disease), evidence of brain
abnormalities showed by magnetic resonance imaging (MRI) (white matter diseases or
enlarged ventricles), cognitive test scores and physical performances [130, 131].
The combined effect of genetic-environmental or environmental-environmental joint expo‐
sures may also lead to the attenuation of the dementia risk. Population-based studies suggest
an effect modification for the APOE ε4 allele, the most important genetic risk factor for sporadic
AD. APOE ε4 carriers seem more vulnerable to risk factors like alcohol drinking, smoking,
physical inactivity and high intake of saturate fat, indicating that people with genetic suscept‐
ibility may reduce their initial AD risk by lifestyle interventions (i.e., physical activity,
sufficient intake of PUFA, and avoiding excess alcohol drinking and smoking) [33]. The
protective effect of lifestyle in APOE ε4 carriers seem to be present also in advanced age: in
the Swedish Kungsholmen Project, subjects aged 75+ years who were APOE ε4 carriers, but
with high education, active leisure activities, or good vascular health (i.e., absence of vascular
risk factors), had a reduced risk of dementia and AD, as well as a delayed time of onset of the
disease [132]. Further, it has been shown that high education may reduce dementia risk among
APOE ε4 allele carriers [133].
Regarding the interactions among modifiable risk factors, results from the Kungsholmen
Project suggested that complexity of work with data and people was related to a decreased
dementia risk and that the highest level of work complexity may modulate the increased
dementia risk due to low education [78].
In conclusion, even though the evidence for some risk and protective factors in dementia and
AD is still scarce, and their role needs to be further clarified, findings from observational
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studies points at different modifiable factors that can be managed in order to prevent or delay
dementia onset. Moreover, epidemiological findings strongly suggest that the life-course
approach model and the multifactorial nature of dementia and AD should be considered when
planning any preventive strategy.
3. Interventional studies
3.1. Current evidence
Different medications, including statins, antihypertensive drugs, estrogens alone or in
combination with progestin (hormone replacement therapy, HRT), nonsteroidal anti-inflam‐
matory drugs (NSAIDs), and nutraceuticals (vitamin B12, C, E, folate, Ginkgo biloba) have
been tested as primary or secondary prevention measures for dementia and AD in subjects
with normal cognition or MCI. In general, for all these compounds the protective effects
suggested by observational studies have not been confirmed in RCTs, the results of which are
inconsistent or even suggest a detrimental effect on cognition (e.g., NSAIDs, HRT) [120,
134-136]. Few interventional studies implementing non-pharmacological approaches have
been carried out. Among them some RCTs on cognitive training and physical activity provided
encouraging results, which need further confirmation [134, 137]. It is possible that the negative
results from the RCTs done so far reflect the real inefficacy of the tested strategies in preventing
dementia and AD. However, the apparent contradiction of results from observational and
interventional studies could be explained by several factors:
1. The intervention was done outside the time-window when management of a risk factor
would reduce dementia risk: several risk factors exert their effect mainly during mid-life,
whereas RCTs have been done in older adults. This is the case for vascular risk factors,
which seem to be more relevant when the exposure occurs during mid-life. Moreover, the
HRT research suggests that estrogens may have beneficial, neutral, or detrimental effects
on the brain depending on age at treatment, type of menopause (natural versus medically
or surgically induced) or stage of menopause [138]. This concept, called the “window of
opportunity hypothesis” is in agreement with the life-course approach model. There is
evidence of neuroprotective effects of estrogens in women before the age of natural
menopause and in the early postmenopausal stage (50-60 years), while estrogens initiated
in late postmenopause (65-79 years) increase the risk of cognitive impairment and
dementia [138-142]. The large-scale RCT of the Women’s Health Initiative Memory Study
(WHI-MS) showed that estrogens therapy alone or in combination with progestin was
associated with a two-fold increased risk for dementia and MCI [139, 140]. The WHI-MS
study enrolled women aged 65-79 years, who were given the HRT many years after the
onset of natural or surgical menopause. In contrast, the Kronos Early Estrogen Prevention
Study (KEEPS) tested the HRT in recently menopausal women (mean age 53 years;
enrolment within three years after menopause), reporting beneficial effects [141]. In fact,
the use of the HRT in the KEEPS participants has been associated with the improvement
of markers of cardiovascular risk, anxiety and depression, without adverse effects on
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cognition [141]. Overall these results suggest that the role of the HRT in age-related
cognition and dementia needs to be further investigated, taking into account the time-
window when the treatment is administered.
2. Short treatment and follow-up: many studies were of relatively short length. Thus,
interventions have been implemented for a period that is not long enough to determine a
neuroprotective effect, and the limited follow-up duration of many RCTs would not allow
detection of differences in dementia incidence.
3. The statistical power was inadequate, since some RCTs had small samples and dementia
has been considered a secondary endpoint in most clinical trials (e.g., antihypertensive
therapy), in which clear benefits for primary endpoints (e.g., coronary heart disease and
stroke) are shown usually in a short period of observation.
4. The choice of compounds tested in RCTs using nutraceuticals was not optimal: although
several products have been tested, supplements composition is still a debated issue. For
instance, whereas observational studies suggested that a balanced intake of different
forms of vitamin E can be important for reducing dementia/AD risk, only one form (α-
tocopherol) has been tested in RCTs, with conflicting findings [84, 85, 107, 108, 143].
Moreover, intake of high doses of α-tocopherol supplements has been associated with
increased hemorrhagic stroke and mortality risk [144]. Regarding the studies on vitamins
B, while the majority of RCTs done so far did not find evidence of benefit [120, 121], a
recent RCT reported favourable effects in subjects with MCI, especially individuals with
elevated homocysteine levels. In this latter RCT supplementation was done using a
combination of vitamins B (B6, B12, folate) at high doses, suggesting that refining the type
of supplements (i.e. composition, concentration) might increases the possibility to achieve
beneficial effects in selected populations [122, 123].
5. Despite the multifactorial nature of dementia and the importance of combined risk
exposures, most studies were based on a mono-intervention approach, almost always
testing single agents or lifestyle interventions. In multifactorial conditions, a small
reduction in multiple risk factors can substantially decrease overall risk.
In conclusion, despite the discrepancies between findings of observational and interventional
studies and the disappointing results of intervention studies on dementia and AD, methodo‐
logical issues of the RCTs carried out thus far suggest that a valid evaluation of the efficacy of
preventive measures has yet to be undertaken.
3.2. Ongoing multidomain intervention studies
The disappointing results of previous trials, testing the effects of mono-intervention strategies
in cognitively normal elderly or already cognitively impaired persons, have pointed out some
key issues: i) timing – starting earlier may lead to better effects; ii) target group – a healthy,
young population would require long follow-up times, large sample sizes and considerable
financial resources; iii) lack of consistent and uniformly applied definitions of MCI has lead to
enrolment of heterogeneous groups underpowering the studies; iv) outcome measures –
cognitive impairment may be a better endpoint than conversion to dementia; v) ethical issues
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are also important, as placebo-controlled trials for high blood pressure and cholesterol are not
possible due to their known protective effects regarding cardio- and cerebrovascular disease.
Furthermore, a critical aspect that needs to be taken into account when planning preventive
measures for dementia and AD, is the multifactorial nature of these disorders, which require
multiple prevention approaches. Intervention studies combining several different approaches
have not been conducted for AD so far, and the knowledge derived from the previously
described observational and interventional studies has paved the way for some ongoing RCTs
on prevention of cognitive decline and dementia. In Europe there are three large ongoing RCTs:
FINGER, MAPT and PreDIVA [145, 146] (Table 2). The common denominator of these studies
is the multidomain approach, which aims to target simultaneously several risk factors for
dementia and AD in older adults, mainly by promoting lifestyle changes and adherence to
medical treatments for vascular risk factors and vascular diseases. All RCTs exclude individ‐
uals with dementia or substantial cognitive decline, and use clinical evaluation and neuro‐
psychological tests to detect cognitive changes and dementia incidence as main outcomes.
Further, secondary outcomes include functional status, mood disorders, quality of life,
adherence to the intervention programs and health resources utilization. These two latter
aspects are essential from a public health perspective, since they provide information on
feasibility and cost effectiveness of prevention strategies. Additionally, both FINGER and
MAPT include ancillary studies on neuroimaging (morphological and functional), CSF and
blood markers related to AD pathophysiology in order to investigate the effect of the inter‐
ventions on brain morphology and metabolism, clarify mechanisms underlying preventive
measures and identify biomarkers that can be used to monitor effects of interventions.
The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability
(FINGER, NCT01041989) is a multicenter RCT aiming to prevent cognitive impairment,
dementia and disability in 60-77 year-old people. The study population is represented by 1282
individuals at increased risk of dementia, selected according to the CAIDE Dementia Risk
Score and the CERAD neuropsychological test battery [128, 145]. The 2-year multidomain
intervention includes nutritional guidance, physical activity, cognitive training, increased
social activity and intensive monitoring and management of metabolic and vascular risk
factors (hypertension, dyslipidemia, obesity, impaired glucose tolerance). Individuals in the
reference group are given general public health advice on lifestyle and vascular risk factors.
FINGER participants are recruited from previous population-based observational surveys (i.e.,
FINRISK, FIN-D2D) with detailed retrospective information on lifestyle and vascular factors
[145]. Thus, differences in these variables can be taken into account, which is normally not
possible in RCTs. The primary outcome is cognitive decline measured by a sensitive Neuro‐
psychological Test Battery (NTB) and the Stroop and Trail Making tests, which can depict early
cognitive impairment typical for AD and VaD. The planned 7-year extended follow-up will
allow detection of differences in dementia/AD incidence. Two earlier intervention trials in
Finland were important sources of inspiration for the FINGER study. The Diabetes Prevention
Study (now completed) is a landmark RCT showing the effectiveness and feasibility of physical
exercise and dietary interventions as preventive measures in people with impaired glucose
tolerance. In this RCT lifestyle intervention in people at high risk for type 2 diabetes resulted
in sustained lifestyle changes and a reduction in diabetes incidence, which remained after the
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individual lifestyle counselling was stopped [147, 148]. The four-year exercise and dietary
intervention study Dose-Responses to Exercise Training (DRs EXTRA) had a drop-out rate of
only 8% after two years, and preliminary results suggested a potential benefit of higher
physical fitness on cognition [149].
RCT
Country
FINGER
Finland
MAPT
France
Pre-DIVA
Netherlands
Sample size 1282 1680 3534
Main inclusion criteria Dementia Risk Score >6
and mild degree of
cognitive impairment
Frail elderly people
(subjective memory
complaint, slow walking
speed, limitation in IADL)
All elderly within GP
practices, non demented
(MMSE >23)
Age at enrolment, yrs 60 -77 ≥ 70 70-78
Study design Multi-center, randomized,
single-blind, parallel-group
Multi-center, randomized,
controlled trial
Multi-site, open, cluster-
randomized parallel
group
Multi-domain intervention Nutritional guidance,
physical activity, cognitive
training, increased social
activity and intensive
monitoring and
management of metabolic
and vascular risk factors
Vascular care, nutritional
advice, exercise advice,
cognitive training,
and/or DHA 800 mg/day
Nurse-led vascular care
including medical
treatment of risk factors,
diet advice, exercise
advice
Intervention period 2 yrs 3 yrs 6 yrs
Follow-up period 7 yrs 5 ysr 6 yrs
Primary outcome Neuropsychological test
battery, Trail Making test,
Stroop test, Dementia
Change in cognitive
function (Grober and
Buschke memory test)
Dementia, Disability
Study Completion 2013 2013 2016
DHA: docosahexaenoic acid acid. IADL: Instrumental Activities of Daily Living. MMSE: Mini Mental State Examination
Table 2. Ongoing multi-domain prevention RCTs on dementia
The Multidomain Alzheimer Preventive Trial (MAPT, NCT00672685) is a French multicenter
RCT evaluating the efficacy of isolated supplementation with ω-3 fatty acid, isolated multi‐
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domain intervention, or their combination in the prevention of cognitive decline in frail
individuals aged ≥70 years. 1680 community-dwelling participants have been enrolled, using
a definition of frailty that includes three components: presence of memory complaints,
limitation in one instrumental activity of daily living (IADL) and slow walking speed. The 3-
year multidomain intervention consists of group training sessions (physical exercise, cognitive
training and nutritional advice) and yearly personalized preventive consultations that aim to
identify dementia and frailty risk factors (vascular risk factors, nutritional problems, sensory
deficits, mood disorders, walking difficulties) and promote their management in collaboration
with the general practitioner. Follow-up is 5 years, and the main outcome measure is the 3-
year change in cognitive function assessed with a neuropsychological test (Grober and
Buschke) [145, 150].
The Prevention of Dementia by Intensive Vascular Care (PreDIVA) study is a Dutch multi‐
center, open, cluster-RCT comparing standard and intensive care of cardiovascular risk factors
in preventing dementia and disability in elderly people. The study includes 3534 community-
dwellers aged 70-78 years, recruited from primary care practices. The standard care is based
on guidelines for Dutch general practice, while the multi-component intensive vascular care
addresses hypertension, hypercholesterolemia, smoking habits, overweight, physical inactiv‐
ity and diabetes mellitus, which are strictly controlled with medication and lifestyle interven‐
tions. Study duration is 6 years, and primary outcomes are incident dementia assessed
according to standard criteria and disability as measured with the AMC Linear Disability Scale
(ALDS) [146].
Researchers involved in these large European trials (FINGER, MAPT and PreDIVA) recently
started the European Dementia Prevention Initiative (EDPI), an international collaboration to
improve preventive strategies against dementia [151]. Collaboration and data sharing within
the EDPI will allow refining methodological aspects of prevention trials, including identifica‐
tion of target populations; improvement of intervention methods (i.e., type, intensity, dura‐
tion); and development and standardization of relevant outcome measures and prognostic and
monitoring tools that can be easily implemented in large populations. This will help planning
larger and international prevention trials able to provide robust evidence on dementia/AD
prevention.
3.3. Presymptomatic Alzheimer’s disease treatment: Anti-amyloid drugs
Presymptomatic (or preclinical) AD treatments have been defined as “those interventions that
are initiated before apparent cognitive decline and are intended to reduce the chance of
developing AD-related symptoms” [152]. The proposed term refers to an intervention whether
it is started before or after biological evidence of the underlying disease, and whether it
postpones the onset, partially reduces the risk of, or completely prevents symptomatic AD
[153]. The progress on the knowledge about the AD phenotype, particularly on the biomarkers
which have been incorporated in the new diagnostic criteria for dementia and MCI due AD,
as well preclinical AD, has provided the basis for intervention studies evaluating pharmaco‐
logical interventions in asymptomatic subjects who are at risk of AD, because of an established
biomarker burden or a specific genetic profile. Three RCTs are planned to start in 2013 to verify
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safety and efficacy of anti-amyloid drugs as preventive measure in AD (Table 3). The Alz‐
heimer’s Prevention Initiative (API) and the Dominantly Inherited Alzheimer's Network
(DIAN) studies will enrol subjects who carry genetic mutations for dominantly inherited AD:
mutations in the APP, presenilin-1 (PSEN1), and presenilin-2 (PSEN2) genes can cause early-
onset familial AD that accounts for no more than 5 percent of all cases [154].
Data from the DIAN study have shown that different phenotypic changes can be detected
several years before the onset of cognitive symptoms in individual with autosomal dominant
AD: it has been shown that CSF levels of Aβ42 decline 25 years before expected symptom onset,
and brain deposition of Aβ can be detected 15 years before. Further, increased concentrations
of tau protein in the CSF and brain atrophy are visible 15 years before expected symptom onset,
while cerebral hypometabolism can be observed 10 years before [155]. The API RCT will focus
on the world largest early-onset AD kindred in Antioquia, Columbia. Of about 5000 individ‐
uals in this kindred, approximately 1500 carry a mutation in the PSEN1 gene (E280A) causing
early onset AD (mean age of onset: 45 years) [156, 157]. The trial will also include a small
number of individuals in the United States, recruited in collaboration with researchers from
the DIAN study [158]. The drug used in the API study is the anti-amyloid antibody crenezu‐
mab, which has been chosen based on the evidence of its ability to remove from the brain
different forms of Aβ and its safety profile (low risk of cerebral vasogenic oedema and
microhaemorrhages) [157]. The trial within the DIAN cohort will include people with muta‐
tions in any of the three genes linked to early-onset AD: PSEN1, PSEN2, and APP. Three
different anti-amyloid compounds will be evaluated in the first phase of the study (2 years):
the beta-secretase inhibitor LY2886721, which limits the production of Aβ; and two anti-
amyloid antibodies (Gantenerumab, Solanezumab) which promote Aβ removal from the
brain. The more effective drug(s) will be further tested in a 3 years extension phase of the study.
A third trial, the Anti-Amyloid Treatment of Asymptomatic Alzheimer’s (A4) RTC, aims to
prevent sporadic AD and will evaluate the effect of an anti-amyloid compound in older adults
with evidence of brain amyloid accumulation at neuroimaging evaluation. The study is
sponsored by the Alzheimer’s Disease Cooperative Study, and also in this case the drug
candidate still needs to be identified among anti-amyloid compounds. The study is expected
to detect differences in the rate of cogntive decline, while it has not enough statistical power
to detect a difference in dementia incidence. The A4 study will also include an ethics arm
examining the psychological impact of disclosing information to individuals about their risk
of developing AD [157].
Overall, these studies provide the opportunity to test the efficacy of AD-modifying treatments
in an earlier stage of AD compared to the pharmacological RCTs done so far. While testing
these compounds in young, healthy individuals would require enormous financial resources
and too long follow up, the recruitment strategies implemented in these studies allow testing
the benefit of anti-amyloid drugs earlier than otherwise possible. This approach provides also
the opportunity to further verify the amyloid hypothesis, which has been reconsidered many
times over the past decades and criticized in light of the recent failures of RCTs testing anti-
amyloid drugs in subjects with mild-to-moderate AD. A possible interpretation of these
failures is that the anti-amyloid therapies have missed their “window of opportunity”, since
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they have been provided too late. The preventive RCTs on anti-amyloid drugs are based on
the assumption that an earlier interference on amyloid accumulation, before irreversible brain
damage occurs, would exert a significant disease-modifying effect. These prevention studies
will also allow determining the ability of different biomarkers to predict a clinical benefit,
information needed to help qualify biomarker endpoints for use in prevention trials. These
studies offer great hope, but also safety concerns, since anti-amyloid compounds will be tested
in subjects with no cognitive problems and the long-term risk associated with the use of anti-
amyloid drugs is yet unknown.
RCT API
Alzheimer’s Prevention
Initiative
DIAN
Dominantly
Inherited Alzheimer
Network
A4
Anti-Amyloid
Treatment of Asymptomatic
AD
Sample size 300 members of Colombian
families.
A small number of individuals
from USA (collaboration with
the DIAN network) will also be
included
240 members of families with
early-onset AD
1500 older adults with no
cognitive impairment
Main inclusion criteria Carriers of a mutated PSEN1
gene. Non-carriers will also be
included, to ensure double-
blinding about the genetic
status
Carriers of mutation in PSEN1,
or PSEN2, or APP. Non-carriers
will also be included, to ensure
double-blinding about the
genetic status
Evidence of brain amyloid
accumulation. Subject with no
evidence of amyloid burden
will also be included
Age at enrolment, yrs ≥ 30 NA ≥ 70
Study design Randomized, double blind,
placebo controlled trial
Randomized, double blind,
placebo controlled trial
Randomized, double blind,
placebo controlled trial
Intervention Anti-amyloid antibody
Crenezumab (Genentech)
Three anti-amyloid therapies:
the beta-secretase inhibitor
LY2886721 (Lilly), and the anti-
amyloid antibodies
Gantenerumab (Roche) and
Solanezumab (Lilly)
One anti-amyloid
therapy (to be determined)
Duration 5 yrs, (interim analysis at 2 yrs) 2 yrs + 3 yrs extension 3 yrs + 2 yrs extension
Outcomes Primary: cognitive function
Secondary: biomarkers,
including brain amyloid load
and brain atrophy
Initial phase (2 yrs): biomarkers
analysis, to identify the most
promising drug candidate
Follow-up phase (3 yrs):
cognitive function
Primary: cognitive function
Secondary: biomarkers
APP: amyloid precursor protein. PSEN1: presenilin 1. PSEN2: presenilin 1
Table 3. Alzheimer’s prevention trials based on anti-amyloid treatments
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4. Conclusion
Prevention is a newer area in dementia/AD research, and the shift from observation to action
has occurred only in the last decade, with several intervention studies now ongoing, and other
RCTs starting soon. Although the pathogenesis of dementia is not fully elucidated, primary
prevention seems possible, as most factors involved in dementia onset and progression are
modifiable or amenable to management. The recent AHRQ/NIH report shows that develop‐
ment of successful preventive strategies requires a more refined knowledge on risk and
protective factors for dementia and AD, as well as a validation of the observational studies
with large intervention studies [19]. AD and VaD share several risk factors, and most dementia
cases are attributable to both vascular and neurodegenerative brain damage. Furthermore,
population-based neuropathological studies have shown that both subclinical neurodegener‐
ative (amyloid plaques, neurofibrillary tangles, Lewy bodies) and vascular lesions are common
in the brains of cognitively normal elderly individuals, as is their co-occurrence [9]. In light of
this, preventive strategies aiming to postpone the onset of dementia syndrome have great
potential.
Epidemiological research suggests that the most effective strategy may be to encourage the
implementation of multiple preventive measures throughout the life course, including high
educational attainment in childhood and early adulthood; active control of vascular factors
and disorders over adulthood; and maintenance of mentally, physically, and socially active
lifestyles during middle age and later in life. It has been estimated that half of AD cases
worldwide are potentially attributable to modifiable risk factors, and a 10-25% reduction in
these factors could potentially prevent 3 million AD cases worldwide, with a reduction in all
risk factors having the greatest impact on dementia prevalence [70]. However, RCTs are
indispensable to confirm the effect of risk reduction strategies targeting multiple risk factors.
Multidomain interventional RCTs are now ongoing and will provide new insights into
prevention of cognitive impairment and dementia. Full implementation of the life-course
approach is more challenging, due to the difficulties of carrying out RCTs over many decades.
Such long-term studies would require very large sample sizes and huge financial resources,
and a pragmatic way to assess the effect of long-term interventions within a RCT has not yet
been established. Furthermore, several risk and protective factors are not appropriate for
intervention trials, due to unethical reasons, thus evidence about these factors rely on con‐
ducting rigorous observational studies (e.g., placebo-controlled trials for high blood pressure
or cholesterol are not possible because such treatments are known to protect against cardio/
cerebrovascular diseases) [35]. Methodological alternatives to RCTs have been proposed to
obtain robust evidence on AD and dementia prevention [37, 159].
Platforms for early intervention could be established by incorporating the classical clinical trial
approach to disease into a public health model, with long-term longitudinal databases
including large populations. Establishing comprehensive databases for studies on aging can
create the opportunity to formulate and validate tools for early detection of people who are at
increased risk of late-life cognitive impairment, to identify important targets (risk factors) for
preventive interventions, and to test such interventions in RCTs.
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The first initiatives with an international perspective have already been established, for
example the Leon Thal Symposia [160], Prevent Alzheimer’s Disease by 2020 (PAD2020, http://
www.pad2020.org), and the European Dementia Prevention Initiative (EDPI, http://
www.edpi.org). It has been suggested that a worldwide database could be built by integrating
and expanding already existing cohorts and registries [160].
The ongoing RTCs on dementia prevention will have to take into account the “window of
opportunity hypothesis” when evaluating the results of interventions. In fact, efficacy of
preventive actions may vary by age. Thus, implementation of interventions at the appropriate
time in the life course is crucial for successful prevention. Refining of prognostic tools, which
can be used for early detection of subjects at risk of dementia in the general population, will
also help to better plan intervention studies. Also, when targeting elderly individuals, the
frequent coexistence of chronic diseases needs to be considered, since it can negatively impact
cognitive performance and limit adherence to preventive interventions. On the other hand,
appropriate management of morbidity can help improve cognitive performance and delay
dementia onset. For instance, although stroke is a known risk factor for dementia, it has been
recently reported that about 25% of stroke patients discontinued one or more of their prescri‐
bed secondary prevention medications within 3 months of hospitalization for acute stroke
[161-163]. Improving long-term adherence to post-stroke treatment can prevent recurrent
cerebrovascular diseases and contribute to preventing or delaying clinical expression of
dementia syndrome. Additionally, there is evidence of inadequate management of hyperten‐
sion and hypercholesterolemia in the older adults [146]. Similar situations exist for heart
failure, which increases the risk of dementia among older adults [68], and diabetes mellitus,
which accelerates the progression from mild cognitive impairment to dementia by more than
3 years [164]. Preliminary results from the PreDIVA study showed that 87% of the study
participants have at least one modifiable risk factor amenable to intervention, proving the
presence of a window of opportunity for improved risk management [146].
In conclusion, prevention of dementia is now moving from observational to interventional
studies to verify hypotheses and define tools that can be applied in the general population.
Epidemiological and preclinical studies will continue to provide new information on risk/
protective factors and pathological mechanisms. The international collaboration among
research teams involved in ongoing multidomain RCTs will allow the sharing of experiences
and discussions on methodological aspects of these studies. This can help in interpretation of
results, identification and solution of problems related to intervention strategies, and refine‐
ment of preventative approaches. The multidomain intervention RCTs are at one end of the
current spectrum of intervention trials in AD/cognitive impairment. At the other end are RCTs
testing disease-modifying drugs (i.e. anti-amyloid therapy) in genetically at-risk groups or
those with established biomarker burden. The shift towards pre-symptomatic and pre-
dementia stages of AD has brought prevention and treatment RCTs much closer to each other
than before. Since a cure for dementia is not yet available, finding effective preventive
strategies is essential for a sustainable society in an aging world. As dementia, cardiovascular
diseases, stroke and diabetes mellitus – all major public health problems – share several risk
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factors, public health efforts promoting healthier lifestyle have the potential to enhance health
status in advanced age.
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